Journal of Clinical Densitometry
Volume 14, Issue 1 , Pages 1-21 , January 2011

Osteoporosis Update From the 2010 Santa Fe Bone Symposium

  • E. Michael Lewiecki

      Affiliations

    • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
    • Corresponding Author InformationAddress correspondence to: E. Michael Lewiecki, MD, FACP, FACE, New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106.
    • ,
  • John P. Bilezikian

      Affiliations

    • Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, NY, USA
    • ,
  • Sundeep Khosla

      Affiliations

    • College of Medicine, Mayo Clinic, Rochester, MN, USA
    • ,
  • Robert Marcus

      Affiliations

    • Stanford University School of Medicine, Stanford, CA, USA
    • ,
  • Michael R. McClung

      Affiliations

    • Oregon Osteoporosis Center, Portland, OR, USA
    • ,
  • Paul D. Miller

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO, USA
    • ,
  • Nelson B. Watts

      Affiliations

    • University of Cincinnati College of Medicine, Cincinnati, OH, USA
    • ,
  • Michael Maricic

      Affiliations

    • Catalina Pointe Rheumatology, Tucson, AZ, USA

Received 1 December 2010 ,Revised 6 December 2010 ,Accepted 6 December 2010.

References 

  1. Lewiecki EM, Baim S, Bilezikian JP, et al. 2008 Santa Fe Bone Symposium: update on osteoporosis. J Clin Densitom. 2009;12(2):135–157
  2. Lewiecki EM, Bilezikian JP, Cooper C, et al. Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. J Clin Densitom. 2008;11(2):313–324
  3. Lewiecki EM. 2006 Proceedings of the Santa Fe Bone Symposium. Womens Health. 2006;2(6):825–828
  4. Lewiecki EM, Bilezikian JP, Laster AJ, et al. 2009 Santa Fe Bone symposium. J Clin Densitom. 2010;13(1):1–9
  5. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 Suppl):S14–S21
  6. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122(2 Suppl):S22–S32
  7. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–759
  8. Bilezikian JP, Matsumoto T, Bellido T, et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2009;24(3):373–385
  9. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–916
  10. Bilezikian JP, Rubin MR. 2006 Monitoring anabolic treatment. In: Dynamics of Bone and Cartilage Metabolism. Vol. 2. Seibel MJ, Robins SP, Bilezikian JP, eds. Elsevier Academic Press, San Diego, CA, 629–647.
  11. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  12. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146(5):326–339
  13. Bilezikian JP. Clinical use of parathyroid hormone in osteoporosis. In: Osteoporosis—Pathophysiology and Clinical Management. 2nd ed.. New York City, NY: Humana Press; 2010;p. 511–526
  14. Ettinger B, San MJ, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19(5):745–751
  15. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93(10):3785–3793
  16. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int. 2004;15(12):992–997
  17. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555–565
  18. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207–1215
  19. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216–1226
  20. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20(11):1905–1911
  21. Cosman F, Eriksen EF, Recknor C, et al. 2010 Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis. J Bone Miner Res 2010 Sep 2 [Epub ahead of print] PMID: 20814967.
  22. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353(6):566–575
  23. Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res. 2009;24(6):1110–1115
  24. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1838–1845
  25. Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009;94(10):3772–3780
  26. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18–22
  27. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–831
  28. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–229
  29. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res. 2007;22:1832–1841
  30. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765
  31. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone. 2009;44(2):199–207
  32. Lewiecki EM. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. IDrugs. 2009;12(12):799–809
  33. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937–947
  34. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95(1):151–158
  35. Fitzpatrick LA, Brennen E, Kumar S, et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J Bone Miner Res. 2008;23(Suppl 1):S50
  36. Fitzpatrick L, Dabrowski C, Cicconetti G, et al. Ronacaleret, a calcium-sensing receptor antagonist: results of a 1 year double-blind, placebo-controlled, dose-ranging phase II study. J Bone Miner Res. 2009;24(Suppl 1):Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=a2c9cbad-2834-4a51-9b49-032e01e0f10cAccessed: August 20, 2010
  37. Horwitz MJ, Tedesco MB, Garcia-Ocana A, et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010;95(3):1279–1287
  38. O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3(8):e2942
  39. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007;38(4):261–269
  40. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95(4):1991–1997
  41. Kousteni S, Bilezikian JP. The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep. 2008;6(2):72–76
  42. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13(4):485–496
  43. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578–588
  44. Yadav VK, Ducy P. Lrp5 and bone formation: a serotonin-dependent pathway. Ann N Y Acad Sci. 2010;1192(1):103–109
  45. Frost M, Andersen TE, Yadav V, et al. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res. 2010;25(3):673–675
  46. Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010;16(3):308–312
  47. Laib A, Ruegsegger P. Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography. Bone. 1999;24(1):35–39
  48. Bailey DA, Wedge JH, McCulloch RG, et al. Epidemiology of fractures of the distal end of the radius in children as associated with growth. J Bone Joint Surg [Am]. 1989;71(8):1225–1231
  49. Khosla S, Melton LJ, Dekutoski MB, et al. Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA. 2003;290(11):1479–1485
  50. Kirmani S, Christen D, van Lenthe GH, et al. Bone structure at the distal radius during adolescent growth. J Bone Miner Res. 2009;24(6):1033–1042
  51. Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res. 2006;21(1):124–131
  52. Melton LJ, Christen D, Riggs BL, et al. Assessing forearm fracture risk in postmenopausal women. Osteoporos Int. 2010;21(7):1161–1169
  53. Melton LJ, Riggs BL, Keaveny TM, et al. Relation of vertebral deformities to bone density, structure and strength. J Bone Miner Res. 2010;25(9):1922–1930
  54. Kristiansen TK, Ryaby JP, McCabe J, et al. Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multicenter, prospective, randomized, double-blind, placebo-controlled study. J Bone Joint Surg [Am]. 1997;79(7):961–973
  55. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg [Am]. 2002;84-A(12):2123–2134
  56. Rozental TD, Vazquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg [Am]. 2009;34(4):595–602
  57. Alharbi M, Pinto G, Finidori G, et al. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res. 2009;71(1):38–44
  58. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14(6):960–968
  59. O’Loughlin PF, Cunningham ME, Bukata SV, et al. Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine. 2009;34(2):121–130
  60. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–414
  61. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738
  62. Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142(9):734–741
  63. National Osteoporosis Foundation . Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008;
  64. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787–2793
  65. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res. 2000;15(10):1965–1973
  66. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93(3):861–868
  67. Bush TL, Wells HB, James MK, et al. Effects of hormone therapy on bone mineral density—results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;276:1389–1396
  68. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 1998;338(8):485–492
  69. Lindsay R, Hart DM, MacLean A, et al. Bone response to termination of oestrogen treatment. Lancet. 1978;1:1325–1327
  70. Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause. 2004;11(6 Pt 1):622–630
  71. McClung M, Miller P, Recknor C, et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol. 2009;114(5):999–1007
  72. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 1998;128(4):253–261
  73. Ravn P, Weiss S, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab. 2000;85:1942–1947
  74. Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med. 2003;163(7):789–794
  75. Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone. 2007;41(3):346–352
  76. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–164
  77. Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26(29):4739–4745
  78. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–955
  79. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–2012
  80. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146(6):416–424
  81. Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–755
  82. Gilchrist NL, Frampton CM, Acland RH, et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007;92(4):1385–1390
  83. National Osteoporosis Foundation . Physician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003;
  84. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589
  85. McClung M. Assessing fracture risk in individual patients. J Watch Womens Health. 2008;12:69–70
  86. Hodgson SF, Watts NB. The 2001 AACE medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001;7:293–312
  87. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2003;87:4431–4437
  88. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363(10):954–963
  89. Consensus conference . Prevention and treatment of kidney stones. J Am Med Assoc. 1988;260(7):977–981
  90. Coe FL, Bushinsky DA. Pathophysiology of hypercalciuria. Am J Physiol. 1984;247(1 Pt 2):F1–F13
  91. Asplin JR, Bauer KA, Kinder J, et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int. 2003;63(2):662–669
  92. Pietschmann F, Breslau NA, Pak CYC. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res. 1992;7:1383–1388
  93. Jaeger P, Lippuner K, Casez JP, et al. Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Miner Res. 1994;9(10):1525–1532
  94. Giannini S, Nobile M, Sartori L, et al. Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol. 1998;50(2):94–100
  95. Da Silva AMM, Dos Reis LM, Pereira RC, et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol. 2002;57(3):183–191
  96. Tasca A, Cacciola A, Ferrarese P, et al. Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urology. 2002;59(6):865–869
  97. Pak CY, Kaplan R, Bone H, et al. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med. 1975;292(10):497–500
  98. Grynpas M, Waldman S, Holmyard D, Bushinsky DA. Genetic hypercalciuric stone-forming rats have a primary decrease in BMD and strength. J Bone Miner Res. 2009;24(8):1420–1426
  99. Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–339
  100. Christensen SE, Nissen PH, Vestergaard P, et al. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol. 2008;159(6):719–727
  101. Fuleihan GE. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res. 2002;17:N51–N56
  102. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–259
  103. Kidney Disease: Improving Global Outcomes (KDIGO) . KDIGO guideline for chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;113(Suppl):S1–S130
  104. Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009;84(8):685–693
  105. Varettoni M, Corso A, Cocito F, et al. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients. Medicine (Baltimore). 2010;89(4):211–216
  106. van der Windt DA, Jellema P, Mulder CJ, et al. Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA. 2010;303(17):1738–1746
  107. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009;20(6):843–851
  108. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009;24(4):561–574
  109. Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res. 2009;24(3):389–397
  110. Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin. 2005;21(7):1015–1026
  111. Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63(1):19–26
  112. Ivaska KK, Gerdhem P, Vaananen HK, et al. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res. 2010;25(2):393–403
  113. Miller P, Bolognese M, Lewiecki E, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 year results of a phase 2 clinical trial. J Bone Miner Res. 2009;24(Suppl 1):Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=1cf516b5-29be-4edf-b1ed-7fa92b4f2031Accessed: October 23, 2009
  114. Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2010;43(Suppl):222–229
  115. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20(6):962–970
  116. Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45(6):1053–1058
  117. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006;119(4 Suppl 1):S25–S31
  118. Miller PD. Monitoring osteoporosis therapies. Curr Osteoporos Rep. 2007;5(1):38–43
  119. Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol. 2005;16(9):2565–2575
  120. Juppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling?. J Bone Miner Res. 2010;25(10):2091–2097
  121. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2(6):595–610
  122. Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S140–S150
  123. Rauch F. Bone biopsy: indications and methods. Endocr Dev. 2009;16:49–57
  124. Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326–331
  125. Gallacher SJ, Ralston SH, Patel U, Boyle IT. Side-effects of pamidronate. Lancet. 1989;2:42–43
  126. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 1999;21(5):389–406
  127. Maalouf NM, Heller HJ, Odvina CV, et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12(1):48–53
  128. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117
  129. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–534
  130. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–761
  131. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1489
  132. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822
  133. U.S. Food and Drug Administration . Update of safety review follow-up to the October 1, 2007. Early communication about the ongoing safety review of bisphosphonates. U.S. Food and Drug Administration; 2008;Rockville, MD. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htmAccessed: March 24, 2010
  134. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89–90
  135. Siris ES, Oster MW, Bilezikian JP. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1791;[Letter]
  136. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1789–1790[Letter]
  137. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1789;[Letter]
  138. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165(3):346–347
  139. Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep. 2005;3(1):5–12
  140. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–2115
  141. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503–508
  142. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809
  143. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf. 2007;6(6):663–672
  144. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35(3):488–497
  145. Miller P, Leigh C, Ward P. Renal tolerability of intravenous ibandronate allows administration by short injection. Ann Rheum Dis. 2006;65(Suppl 2):422
  146. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74(5):641–648
  147. Miller PD. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol. 2009;29(2):144–155
  148. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15(4):613–620
  149. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–1301
  150. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93(8):2948–2952
  151. Armamento-Villareal R, Napoli N, Diemer K, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009;85(1):37–44
  152. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg [Am]. 2009;91(11):2556–2561
  153. Odvina CV, Levy S, Rao S, et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72(2):161–168
  154. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg [Br]. 2007;89(3):349–353
  155. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–350
  156. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20(8):1353–1362
  157. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–1102
  158. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–1771
  159. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–2294
  160. Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199
  161. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938
  162. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19(3):365–372
  163. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):462–468
  164. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25(5):976–982
  165. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632–637
  166. U.S. Food and Drug Administration, FDA . FDA Drug Safety Communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. U.S. Food and Drug Administration; 2010;Rockville, MD. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htmAccessed: March 23, 2010
  167. Somford MP, Draijer FW, Thomassen BJ, et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24(10):1736–1740
  168. Mishra A, Wong L, Jonklaas J. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine. 2001;14(2):159–164

PII: S1094-6950(10)00290-8

doi: 10.1016/j.jocd.2010.12.001

Journal of Clinical Densitometry
Volume 14, Issue 1 , Pages 1-21 , January 2011

Article Tools

* Image Usage & Resolution